Within this context, it is reasonable to suggest that the combination of MAPK/ERK and PI3K/AKT inhibitors can affect the antioxidant systems, and therefore might have the potential to enhance anticancer effect in ALL and AML cells. This evidence concerns the gene MAPK1 and acute myeloid leukemia.